Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

jvbiotek Jan. 14 at 3:51 AM

$FBIOP $FBIO why is FBIO going down and FBIOP going up? I took position in FBIO.. did I make a mistake?

0 · Reply

makrodimutross Jan. 14 at 2:27 AM

$FBIOP $FBIO I'm still in the clear here! FBIO won't reach 7 until FBIOP gets to 15 first.

1 · Reply

makrodimutross Jan. 14 at 2:26 AM

$FBIO $FBIOP Who's still here for Triplex?

1 · Reply

FinSUN Jan. 13 at 10:53 PM

$FBIOP very good close. Very good swap today. Pardon me if I will still trade 20% of my position, presumably on a weekly base.

0 · Reply

makrodimutross Jan. 13 at 6:55 PM

$FBIOP Tremendously smooth brains deciding to short this over the winter. The Zydus conference call was early November, wherein their management team confirmed that they were planning to *Launch* CUTX-101 in 1H2026. This was an obvious Class 1/2 resubmission. I am interested to see how much of this was covered today, or if this SI has increased with today's volume. With the PRV in hand, this will obviously reach liquidation preference within 6 months. Cyprium PPS is going to be paid out at 2x liquidation preference ($50 per share). This is still on for half price.

1 · Reply

deembi Jan. 13 at 6:50 PM

$FBIOP $FBIO telltale signs of a preferred - equity swap?

1 · Reply

Kconn52 Jan. 13 at 6:43 PM

$FBIOP this continues to be an incredible bargain. If you deduct the unpaid accumulated dividends, the yield is spectacular. Obviously, we have very little visibility on when the dividend will be paid and restored and that’s why this remains so cheap. The fact that they must restore or otherwise cure the dividend to access the equity issuance market provides the needed incentive to get this fixed. The ROC treatment of the dividends makes the payment, when received, very tasty!

0 · Reply

IBUYSELLHOLD Jan. 13 at 6:35 PM

$FBIOP /looks like it's very risky buying more here

1 · Reply

Sawnchey Jan. 13 at 5:51 PM

$FBIO $FBIOP Good to see the PR drop. I am hoping next that they are able to sell the PRV before the end of the quarter, it would be great to see the cash reflected in the Q1 financial reporting. Especially alongside Unloxcyt +/- Zycubo launch and that first little trickle of revenue!

0 · Reply

dsoape Jan. 13 at 5:24 PM

$FBIOP was a nice call you made on the preferred, congrats

1 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A